IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice

P. Schwarzenberger, W. Huang, P. Oliver, P. Byrne, V. La Russa, Z. Zhang, J. K. Kolls

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Autologous and allogeneic bone marrow transplantations have evolved as important cancer therapy modalities. For both indications, peripheral blood has been shown to have distinct advantages over bone marrow as the stem cell source. Cytokine combinations for mobilization have enhanced stem cell yield and accelerated engraftment. However, novel mobilizing agents and strategies are needed to further improve clinical outcomes. Within the donor graft, the dynamic equilibrium between T cells and stem cells critically influences engraftment and transplantation results. IL-17 is a cytokine produced almost exclusively from activated T cells. IL-17 was expressed in vivo with adenovirus technology. Here, proof-of-principle studies demonstrate that IL-17 effectively mobilizes hemopoietic precursor cells (CFU-granulocyte-erythrocyte-macrophage-monocyte, CFU-high proliferative potential) and primitive hemopoietic stem cells (Lin-/lowc-kit+Sca1+). Moreover, mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated mice. Bone marrow was found to be 45-75% of donor origin at 1 year. In secondary recipients, donor-derived bone marrow cells ranged from 45 to 95%. These data show that IL-17 mobilizes stem cells in mice with short- and long-term reconstituting capacity. Additional comparative studies are needed as well as studies in tumor models to refine distinct potential clinical applications for IL-17-mobilized peripheral blood stem cells.

Original languageEnglish
Pages (from-to)2081-2086
Number of pages6
JournalJournal of Immunology
Volume167
Issue number4
StatePublished - Aug 15 2001

Fingerprint

Interleukin-17
Stem Cells
Adenoviridae
Bone Marrow
Cytokines
T-Lymphocytes
Granulocyte Precursor Cells
Homologous Transplantation
Bone Marrow Transplantation
Bone Marrow Cells
Peripheral Blood Stem Cells
Monocytes
Neoplasms
Transplantation
Erythrocytes
Macrophages
Technology
Transplants

ASJC Scopus subject areas

  • Immunology

Cite this

Schwarzenberger, P., Huang, W., Oliver, P., Byrne, P., La Russa, V., Zhang, Z., & Kolls, J. K. (2001). IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice. Journal of Immunology, 167(4), 2081-2086.

IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice. / Schwarzenberger, P.; Huang, W.; Oliver, P.; Byrne, P.; La Russa, V.; Zhang, Z.; Kolls, J. K.

In: Journal of Immunology, Vol. 167, No. 4, 15.08.2001, p. 2081-2086.

Research output: Contribution to journalArticle

Schwarzenberger, P, Huang, W, Oliver, P, Byrne, P, La Russa, V, Zhang, Z & Kolls, JK 2001, 'IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice', Journal of Immunology, vol. 167, no. 4, pp. 2081-2086.
Schwarzenberger P, Huang W, Oliver P, Byrne P, La Russa V, Zhang Z et al. IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice. Journal of Immunology. 2001 Aug 15;167(4):2081-2086.
Schwarzenberger, P. ; Huang, W. ; Oliver, P. ; Byrne, P. ; La Russa, V. ; Zhang, Z. ; Kolls, J. K. / IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice. In: Journal of Immunology. 2001 ; Vol. 167, No. 4. pp. 2081-2086.
@article{e791846d7b314d6ea8a3ec641d2783fa,
title = "IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice",
abstract = "Autologous and allogeneic bone marrow transplantations have evolved as important cancer therapy modalities. For both indications, peripheral blood has been shown to have distinct advantages over bone marrow as the stem cell source. Cytokine combinations for mobilization have enhanced stem cell yield and accelerated engraftment. However, novel mobilizing agents and strategies are needed to further improve clinical outcomes. Within the donor graft, the dynamic equilibrium between T cells and stem cells critically influences engraftment and transplantation results. IL-17 is a cytokine produced almost exclusively from activated T cells. IL-17 was expressed in vivo with adenovirus technology. Here, proof-of-principle studies demonstrate that IL-17 effectively mobilizes hemopoietic precursor cells (CFU-granulocyte-erythrocyte-macrophage-monocyte, CFU-high proliferative potential) and primitive hemopoietic stem cells (Lin-/lowc-kit+Sca1+). Moreover, mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated mice. Bone marrow was found to be 45-75{\%} of donor origin at 1 year. In secondary recipients, donor-derived bone marrow cells ranged from 45 to 95{\%}. These data show that IL-17 mobilizes stem cells in mice with short- and long-term reconstituting capacity. Additional comparative studies are needed as well as studies in tumor models to refine distinct potential clinical applications for IL-17-mobilized peripheral blood stem cells.",
author = "P. Schwarzenberger and W. Huang and P. Oliver and P. Byrne and {La Russa}, V. and Z. Zhang and Kolls, {J. K.}",
year = "2001",
month = "8",
day = "15",
language = "English",
volume = "167",
pages = "2081--2086",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - IL-17 mobilizes peripheral blood stem cells with short- and long-term repopulating ability in mice

AU - Schwarzenberger, P.

AU - Huang, W.

AU - Oliver, P.

AU - Byrne, P.

AU - La Russa, V.

AU - Zhang, Z.

AU - Kolls, J. K.

PY - 2001/8/15

Y1 - 2001/8/15

N2 - Autologous and allogeneic bone marrow transplantations have evolved as important cancer therapy modalities. For both indications, peripheral blood has been shown to have distinct advantages over bone marrow as the stem cell source. Cytokine combinations for mobilization have enhanced stem cell yield and accelerated engraftment. However, novel mobilizing agents and strategies are needed to further improve clinical outcomes. Within the donor graft, the dynamic equilibrium between T cells and stem cells critically influences engraftment and transplantation results. IL-17 is a cytokine produced almost exclusively from activated T cells. IL-17 was expressed in vivo with adenovirus technology. Here, proof-of-principle studies demonstrate that IL-17 effectively mobilizes hemopoietic precursor cells (CFU-granulocyte-erythrocyte-macrophage-monocyte, CFU-high proliferative potential) and primitive hemopoietic stem cells (Lin-/lowc-kit+Sca1+). Moreover, mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated mice. Bone marrow was found to be 45-75% of donor origin at 1 year. In secondary recipients, donor-derived bone marrow cells ranged from 45 to 95%. These data show that IL-17 mobilizes stem cells in mice with short- and long-term reconstituting capacity. Additional comparative studies are needed as well as studies in tumor models to refine distinct potential clinical applications for IL-17-mobilized peripheral blood stem cells.

AB - Autologous and allogeneic bone marrow transplantations have evolved as important cancer therapy modalities. For both indications, peripheral blood has been shown to have distinct advantages over bone marrow as the stem cell source. Cytokine combinations for mobilization have enhanced stem cell yield and accelerated engraftment. However, novel mobilizing agents and strategies are needed to further improve clinical outcomes. Within the donor graft, the dynamic equilibrium between T cells and stem cells critically influences engraftment and transplantation results. IL-17 is a cytokine produced almost exclusively from activated T cells. IL-17 was expressed in vivo with adenovirus technology. Here, proof-of-principle studies demonstrate that IL-17 effectively mobilizes hemopoietic precursor cells (CFU-granulocyte-erythrocyte-macrophage-monocyte, CFU-high proliferative potential) and primitive hemopoietic stem cells (Lin-/lowc-kit+Sca1+). Moreover, mouse IL-17 adenovirus-mobilized peripheral blood stem cells rescued lethally irradiated mice. Bone marrow was found to be 45-75% of donor origin at 1 year. In secondary recipients, donor-derived bone marrow cells ranged from 45 to 95%. These data show that IL-17 mobilizes stem cells in mice with short- and long-term reconstituting capacity. Additional comparative studies are needed as well as studies in tumor models to refine distinct potential clinical applications for IL-17-mobilized peripheral blood stem cells.

UR - http://www.scopus.com/inward/record.url?scp=0035881579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035881579&partnerID=8YFLogxK

M3 - Article

C2 - 11489991

AN - SCOPUS:0035881579

VL - 167

SP - 2081

EP - 2086

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -